Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 1
2012 1
2013 4
2014 2
2015 5
2016 4
2017 4
2018 2
2019 1
2020 3
2021 4
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC. Chiang CL, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):169-178. doi: 10.1016/S2468-1253(22)00339-9. Epub 2022 Dec 15. Lancet Gastroenterol Hepatol. 2023. PMID: 36529152 Clinical Trial.
METHODS: START-FIT was a single-arm, phase 2 trial in patients with locally advanced hepatocellular carcinoma who were not suitable for curative treatment, conducted in two hospitals in Hong Kong and one in Shenzhen, China. Eligible patients were those …
METHODS: START-FIT was a single-arm, phase 2 trial in patients with locally advanced hepatocellular carcinoma wh …
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advance …
Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology …
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M. Lyu N, et al. J Clin Oncol. 2022 Feb 10;40(5):468-480. doi: 10.1200/JCO.21.01963. Epub 2021 Dec 14. J Clin Oncol. 2022. PMID: 34905388 Clinical Trial.
PURPOSE: Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving pati …
PURPOSE: Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed a …
Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
Chen J, Zhang D, Yuan Y. Chen J, et al. Clin Exp Med. 2023 Jul;23(3):579-590. doi: 10.1007/s10238-022-00873-6. Epub 2022 Aug 26. Clin Exp Med. 2023. PMID: 36018466 Review.
But more than 80% of HCC patients cannot be fitful for radical therapies because of local progression or distant metastasis at initial diagnosis. Among patients with unresectable locally advanced hepatocellular carcinoma (HCC), some patients can be con …
But more than 80% of HCC patients cannot be fitful for radical therapies because of local progression or distant metastasis at initial diagn …
Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma.
Shiba S, Shibuya K, Okamoto M, Okazaki S, Komatsu S, Kubota Y, Nakano T, Ohno T. Shiba S, et al. Radiat Oncol. 2020 Aug 14;15(1):195. doi: 10.1186/s13014-020-01634-z. Radiat Oncol. 2020. PMID: 32795340 Free PMC article. Clinical Trial.
Direct invasion of the major branch of the portal vein, hepatic vein, or both portal and hepatic veins was observed in three, five, and three patients, respectively. The 3-year overall survival, local control, and progression-free survival rates were 64, 78, and 18%, respe …
Direct invasion of the major branch of the portal vein, hepatic vein, or both portal and hepatic veins was observed in three, five, a …
Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion.
Blaise L, Pereira H, Vilgrain V, Sutter O, Gigante E, Walter A, Ganne-Carrié N, Nahon P, Bouattour M, Dioguardi Burgio M, Grando V, Nkontchou G, Seror O, Nault JC. Blaise L, et al. Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101731. doi: 10.1016/j.clinre.2021.101731. Epub 2021 Jun 15. Clin Res Hepatol Gastroenterol. 2021. PMID: 34139320 Clinical Trial.
METHODS: We included 272 patients with HCC and tumor portal invasion treated by percutaneous ablation (n = 44) assessed retrospectively from one center compared to a control group from the SARAH trial including patients treated with sorafenib (n = 123) or TARE (n = 105). A propen …
METHODS: We included 272 patients with HCC and tumor portal invasion treated by percutaneous ablation (n = 44) assessed retrospectively from …
Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study.
Chen S, Yuan B, Yu W, Wang X, He C, Chen C. Chen S, et al. J Gastrointest Surg. 2022 Nov;26(11):2292-2300. doi: 10.1007/s11605-022-05421-x. Epub 2022 Aug 3. J Gastrointest Surg. 2022. PMID: 35920966
We aimed to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) for locally advanced HCC compared to transcatheter arterial chemoembolization (TACE). METHODS: A propensity score-matched cohort study was performed in patients with locally advan …
We aimed to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) for locally advanced HCC compared to transcath …
Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and (18) F-fluoro-2-deoxyglucose positron emission tomography.
Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Rhee WJ, et al. Liver Int. 2017 Apr;37(4):592-599. doi: 10.1111/liv.13297. Epub 2016 Nov 27. Liver Int. 2017. PMID: 27804192
BACKGROUND & AIMS: We investigated the significance of (18) F-fluoro-2-deoxyglucose positron emission tomography ((18) F-FDG PET) parameters and alpha-foetoprotein (AFP) levels in patients with locally advanced hepatocellular carcinoma (LA-HCC). ME …
BACKGROUND & AIMS: We investigated the significance of (18) F-fluoro-2-deoxyglucose positron emission tomography ((18) F-FDG PET) parame …
Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma.
Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, Lai L, Hazirah SN, Lim TKH, Goh BKP, Chung A, Lo RHG, Ng D, Filarca RLF, Albani S, Chow PKH. Chew V, et al. Gut. 2019 Feb;68(2):335-346. doi: 10.1136/gutjnl-2017-315485. Epub 2018 Feb 13. Gut. 2019. PMID: 29440463 Free PMC article.
OBJECTIVES: Yttrium-90 (Y90)-radioembolisation (RE) significantly regresses locally advanced hepatocellular carcinoma and delays disease progression. ...Potential biomarkers associated with a positive clinical response were identified and a predicti …
OBJECTIVES: Yttrium-90 (Y90)-radioembolisation (RE) significantly regresses locally advanced hepatocellular carcinom …
Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child-Pugh grade B patients with locally advanced hepatocellular carcinoma.
Li JX, Zhang RJ, Qiu MQ, Yan LY, He ML, Long MY, Zhong JH, Lu HY, Zhou HM, Xiang BD, Liang SX. Li JX, et al. Radiat Oncol. 2023 Mar 8;18(1):48. doi: 10.1186/s13014-023-02232-5. Radiat Oncol. 2023. PMID: 36890592 Free PMC article.
Two patients (2.7%) exhibited a transaminase elevation of G3, fourteen (18.7%) exhibited a Child-Pugh score increase of 2, and one (1.3%) demonstrated both a transaminase elevation of G3 and a Child-Pugh score increase of 2. No cRILD cases were observed. A me …
Two patients (2.7%) exhibited a transaminase elevation of G3, fourteen (18.7%) exhibited a Child-Pugh score increase of 2, and one (1 …
34 results